Breast Cancer awareness starts with prevention.

Breast Cancer awareness starts with prevention.
Enjoy 10% off for Patient Appreciation Day with code THANKYOU10 on 10/15/2026 only! Shop Now >
Estrogen, progesterone and testosterone all decline as women move through perimenopause and into menopause, and research shows that symptoms meaningfully affect quality of life for the majority of women who experience this transition. For many, this shift quietly disrupts sleep, mood, energy, cognitive clarity and sexual health. Bioidentical hormone replacement therapy is one approach that prescribers may consider when addressing these changes. BHRT uses hormones that are structurally identical to those the body produces naturally, and a compounding pharmacy can prepare customized formulations in the combination, strength and delivery method a prescriber specifies. Options may include implantable pellets, transdermal creams and gels, sublingual tablets, troches and vaginal preparations. It is also worth knowing that the breast cancer and cardiovascular concerns many women associate with hormone therapy are more nuanced than widely understood. Research has shown that the type of progestogen used matters significantly, and that the timing of hormone therapy initiation relative to menopause has a substantial effect on cardiovascular outcomes. For those looking to support their wellness now, over-the-counter options such as Pro-Balance DHEA and Pro-Balance Vitamin D3 5,000 IU are available for immediate purchase without a prescription.
I finally feel like I have a team that actually listens. My provider and pharmacist worked together to find the right approach for me, and for the first time in years I feel like myself again.
Costs vary depending on the type of medication, dosage form and frequency of use. Because compounded medications are customized, pricing is determined on a per-prescription basis. Speak with a pharmacist to get a clearer picture of what to expect for your specific prescription.
When prescribed and monitored appropriately, hormone therapy may support improvements in sleep, mood, energy, cognitive clarity, sexual health and bone density. Research also suggests that hormone therapy initiated near the time of menopause may be associated with cardiovascular benefit and reduced risk of osteoporosis. Individual responses vary, and your healthcare provider can help you understand what may be relevant for your situation.
This question is more nuanced than many people realize. The concern largely originated from the Women’s Health Initiative study, which used synthetic progestins rather than bioidentical progesterone. Subsequent research, including a large French cohort study, found that bioidentical progesterone combined with estradiol was not associated with the increased breast cancer risk observed with synthetic progestins. The type of hormone used matters significantly. Your healthcare provider will evaluate your individual history before making any clinical decisions.
Timing appears to be the critical factor. Evidence supporting the timing hypothesis, including findings from the KEEPS trial and the Danish Osteoporosis Prevention Study, suggests that women who begin hormone therapy within ten years of menopause or before age 60 may experience cardiovascular benefit rather than increased risk. The Women’s Health Initiative enrolled women with an average age of 63, many years past menopause, which contributed to a different risk profile. Speak with a provider who understands the current research before drawing conclusions.
Yes. Bioidentical hormones are structurally identical to the hormones the body produces naturally, including estradiol, progesterone and testosterone. Conventional hormone therapy has historically used synthetic derivatives such as medroxyprogesterone acetate, which bind to receptors differently and may carry a different safety profile. Compounded bioidentical hormones can also be customized in strength and delivery form in ways that commercially manufactured products cannot.
Yes. Perimenopause, the transitional phase leading up to menopause, can begin in the early to mid 40s and sometimes earlier. During this phase, hormone levels fluctuate significantly even while periods continue. Symptoms such as irregular cycles, sleep disruption, mood changes, brain fog and changes in libido can all occur before menopause is reached. Blood testing combined with symptom evaluation can help your provider get a clearer picture of what is happening hormonally.
Decisions about starting, adjusting or discontinuing therapy should be made in consultation with your healthcare provider. Stopping therapy may lead to a return of symptoms, and the approach to discontinuation should be guided by your provider based on your individual situation and goals.
Compounding pharmacies can prepare estradiol, progesterone and testosterone in several forms including transdermal creams, troches, sublingual tablets, vaginal preparations and implantable pellets. The form prescribed depends on your healthcare provider’s assessment of which option offers the most appropriate absorption and tolerability for your individual needs.
If you do not currently have a provider who specializes in hormone health, a compounding pharmacy may be able to help connect you with practitioners in your area who offer this type of care. You can also ask your primary care physician for a referral or speak directly with a pharmacist.
[1] North American Menopause Society. Menopause Practice: A Clinician’s Guide. https://www.menopause.org/for-clinicians/clinical-resources
[2] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
[3] Shuster LT, et al. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65(2):161-166. https://pubmed.ncbi.nlm.nih.gov/19733988/
[4] Prior JC. Progesterone for Symptomatic Perimenopause Treatment. J Obstet Gynaecol Can. 2011;33(12):1294-1301. https://pubmed.ncbi.nlm.nih.gov/22166192/
[5] Avis NE, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. https://pubmed.ncbi.nlm.nih.gov/25686030/
[6] Fournier A, et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. https://pubmed.ncbi.nlm.nih.gov/17333341/
[7] Asi N, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev. 2016;5(1):121. https://pubmed.ncbi.nlm.nih.gov/27405577/
[8] Harman SM, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005;8(1):3-12. https://pubmed.ncbi.nlm.nih.gov/15823848/
[9] Schierbeck LL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. https://pubmed.ncbi.nlm.nih.gov/23048011/
[10] Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938. https://pubmed.ncbi.nlm.nih.gov/28898378/
Tell us a little about what you are looking for and we will take it from there. Whether you have a prescription ready, questions about a therapy your provider mentioned, or just need help figuring out your next step, our team is here and ready to help.
"*" indicates required fields
To submit your order, click the “PRINT/SAVE” button located under this pop-up.Â
You can save the PDF to your computer to fax at a later date or print it now to fax immediately. Â
Fax your order form to 817-860-6083 for processing.
Get detailed information, research, and deeper product context. Toggle on to see more educational content.
Keep things brief and see related products faster. Toggle on to focus on products.
New to Pharmacy Solutions? Register now